

ORIGINAL INVESTIGATION

Open Access

Heart-Type Fatty Acid Binding Protein (H-FABP): Relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with impaired glucose metabolism

Basak Karbak^{1*}, Mustafa Özbek¹, Nujen Colak Bozkurt¹, Zeynep Ginis², Askin Güngünes¹, İlknur Öztürk Ünsal¹, Erman Cakal¹ and Tuncay Delibası¹

Abstract

Background: Heart type fatty acid binding protein (H-FABP) has been closely associated with acute coronary syndrome, cardiac abnormalities, stroke, and obstructive sleep disorder in previous studies. The aim of this study was to evaluate and compare the serum H-FABP levels and carotid artery intima-media thickness (CIMT) between patients with prediabetes and control subjects.

Research design and methods: We measured serum H-FABP levels in 58 prediabetic patients, 29 with impaired fasting glucose (IFG) and 29 with impaired glucose tolerance (IGT) and 28 age-, sex- and body mass index-matched control subjects using a sandwich enzyme-linked immunosorbent assay (ELISA), and in order to measure CIMT, all participants underwent high-resolution B-mode ultrasonography.

Results: Serum H-FABP levels were significantly elevated in pre-diabetic patients when compared with that of control subjects (IFG: 32.5 ± 34.2 ng/dL, IGT: 45.4 ± 45.8 ng/dL, control: 16.8 ± 14.9 ng/dL; $p = 0.011$). The difference in means of H-FABP levels between patients with IGT or IFG and control subjects was significant ($p = 0.010$ and $p = 0.009$, respectively). CIMT was higher in the pre-diabetic groups compared with the control group (IFG: 0.6 ± 0.1 , IGT: 0.6 ± 0.1 , control: 0.5 ± 0.1 ; $p < 0.001$), and H-FABP level was positively correlated with CIMT ($p < 0.001$, $\rho = 0.626$).

Conclusion: Our results indicate that patients with pre-diabetes are at increased risk for cardiovascular disease. In addition, serum H-FABP levels could represent a useful marker for myocardial performance in patients with IFG and IGT.

Background

Abnormalities of glucose metabolism are most commonly diagnosed using the threshold criteria for impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) established by the American Diabetes Association (ADA) and the World Health Organization (WHO) [1-3]. These two pre-diabetic states were initially recognized as conditions associated with increased risk of progression to type 2 diabetes mellitus. In addition to the elevated

glucose levels, pre-diabetes is associated with the classic cardiovascular risk factors, such as obesity, hypertension, and dyslipidemia [4-6]. IGT and IFG differ from one another in many aspects, including the associated cardiovascular risk [7]. Whereas ample evidence points to a strong relationship between IGT and cardiovascular morbidity and mortality, it is still unclear whether there is a relationship between IFG and cardiovascular disease [8,9].

Heart-type fatty acid binding protein (H-FABP) is abundant in the cytosol of cardiomyocytes, and transports fatty acids in these cells. It is a powerful regulator of the mitochondrial beta-oxidative system in the heart [10]. Molecular size and intracellular location are important factors

* Correspondence: b_karbak@yahoo.com

¹Department of Endocrinology and Metabolism, Dışkapı Yıldırım Beyazıt Teaching and Research hospital, Ankara, Turkey

Full list of author information is available at the end of the article

determining the kinetic release of cardiac biomarkers. Small cytoplasmic molecules such as H-FABP (15 kDa) appear earlier (2-4 h) than larger ones, which are mainly associated with myofibrils, as cardiac troponins (6-12 h) [11]. Therefore, H-FABP has been used as a diagnostic marker for acute coronary syndrome (ACS). Other studies have demonstrated that serum levels of H-FABP are increased in patients with hypertrophic and dilated cardiomyopathy, heart failure, stroke, obstructive sleep apnea, and pulmonary embolism [12]. Carotid artery intima-media thickness (CIMT) is an intermediate phenotype for early atherosclerosis. High CIMT values have been associated with cardiovascular disease, coronary atherosclerosis, and related risk factors in cross-sectional studies [13,14]. Further, since CIMT can be measured relatively simply and noninvasively, it represents a useful diagnostic tool.

The aim of the present study was to compare serum H-FABP levels, CIMT, and cardiovascular risk factors of IFG and IGT patients with those of controls having normal glucose tolerance (NGT). In addition, to discern any possible differences between the two pre-diabetic groups, values for these three parameters in IFG patients were compared with those in IGT patients.

Materials and methods

The present study was performed at the Endocrinology Department of Diskapi Yildirim Beyazit Training and Research Hospital, during the period January 2010-July 2010. Fifty-eight patients with pre-diabetes (29 with IGT, mean age: 46.9 ± 10.4 years, and 29 with IFG, mean age: 45.2 ± 10.3 years) along with 28 control subjects with NGT, matched for age, gender, and body mass index (BMI), were enrolled. The demographic characteristics of the case and control subjects are shown in Table 1. The study was approved by the Hospital Ethical Committee and informed consents were obtained from all participants before the study procedures.

All participants underwent a standard 75 g oral glucose tolerance test (OGTT) after 12 h fast, with venous glucose sampling at 0 min and 120 min. Categories of glucose tolerance were defined according to 2006 WHO criteria [15]. IFG is defined by an elevated fasting plasma glucose (FPG) concentration (≥ 100 and < 126 mg/dL). IGT is defined by an elevated 2-hour plasma glucose concentration (≥ 140 and < 200 mg/dL) after a 75-g glucose load on the oral glucose tolerance test (OGTT) in the presence of an FPG concentration < 126 mg/dL. Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides, and fasting serum insulin were estimated. Weight and height of the subjects were measured, and BMI and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. All participants underwent

high-resolution B-mode ultrasonography. All scans and image measurements were carried out by the same investigator, who was blinded to the risk factor status of the participants. All patients were interviewed using a standard questionnaire, including demographic characteristics, concomitant disease, use of medications that could affect blood glucose and H-FABP levels and smoking history, and they underwent physical examination. Patients with a history of ACS, heart failure, pulmonary embolism, stroke, cardiomyopathy, renal disease and immunological diseases, or those who were under treatment for these diseases, were excluded from the study. The control group composed of volunteers who did not have any history of cardiometabolic disease, ACS, heart failure, pulmonary embolism, stroke, cardiomyopathy, renal disease, immunological diseases, and diabetes mellitus.

Heart-type fatty acid binding protein

The human H-FABP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle. Samples and standards are incubated together with peroxidase-conjugated second antibody in microtiter wells coated with antibodies recognizing human H-FABP. During incubation human H-FABP is captured by the solid bound antibody. The secondary antibodies will bind to the captured human H-FABP. The peroxidase conjugated antibody will react with the substrate, tetramethylbenzidine (TMB). The enzyme reaction is stopped by the addition of oxalic acid. The absorbance at 450 nm is measured with a spectrophotometer.

Statistical analyses

The Statistical Package for Social Sciences (SPSS) version 15.0 for Windows was used for the statistical analyses. Frequency tables for categorical variables and descriptive statistics (mean, standard deviation, median, minimum, maximum) for the numerical variables were generated. Providing the crosstab statistics for the inter-group categorical comparisons, significance levels were examined using a chi-square test. A t-test was performed to determine differences among groups for the normally distributed data. For non-normally distributed data, the Mann-Whitney U test was performed for two-group comparisons and the Kruskal-Wallis test was used for multi-group comparisons. In order to measure dependence between groups that were not normally distributed, Spearman's rho coefficient was calculated. A p value < 0.05 was considered statistically significant.

Results


Demographic characteristics and biochemical parameters of the patients with IGT, the patients with IFG, and normal control subjects are shown in Table 1.

Table 1 Demographic characteristics and biochemical data for patients with impaired fasting glucose (IFG), patients with impaired glucose tolerance (IGT), and control subjects

	IFG (n = 29)	IGT (n = 29)	Control (n = 28)	p
Gender, n (%)				
Female	23 (79.3)	23 (79.3)	23 (82.1)	0.953
Male	6 (20.7)	6 (20.7)	5 (17.9)	
Age (Years), mean ± SD	45.2 ± 10.3	46.9 ± 10.4	44.2 ± 8.1	0.575
BMI (kg/m²), mean ± SD	27.9 ± 2.4	28.6 ± 3.6	28.6 ± 4.1	0.652
Waist/hip ratio, mean ± SD	0.90 ± 0.07	0.87 ± 0.07	0.85 ± 0.08	0.047
Hypertension, n (%)				
Absent	28 (96.6)	27 (93.1)	28 (100.0)	0.770
Present	1 (3.4)	2 (6.9)	0 (0)	
Smoking, n (%)				
Absent	26 (89.7)	24 (82.8)	25 (89.3)	0.784
Present	3 (10.3)	5 (17.2)	3 (10.7)	
Total cholesterol level (mg/dL), mean ± SD	184.9 ± 27.2	187.6 ± 34.9	198.1 ± 23.3	0.110
LDL level (mg/dL), mean ± SD	117.7 ± 40.3	105.9 ± 32.6	118.2 ± 23.7	0.204
HDL level (mg/dL), mean ± SD	47.9 ± 10.2	52.2 ± 27.3	51.3 ± 11.7	0.533
TG level (mg/dL), mean ± SD	120.9 ± 38.9	148.0 ± 68.9	131.6 ± 48.2	0.364
Fasting blood glucose level (mg/dL), mean ± SD	111.1 ± 5.9	105.1 ± 8.5	92.3 ± 5.0	<0.001
Insulin level, mean ± SD	11.9 ± 4.8	13.1 ± 5.4	9.10 ± 4.2	0.008
HOMA-IR level, mean ± SD	3.4 ± 1.4	4.1 ± 1.7	2.1 ± 1.0	<0.001

HOMA-IR: Homeostatic model assessment BMI: Body mass index.

Serum H-FABP levels were significantly elevated in pre-diabetic patients compared with control subjects (IFG: 32.5 ± 34.2 ng/dL, IGT: 45.4 ± 45.8 ng/dL, control: 16.8 ± 14.9 ng/dL; $p = 0.011$, Figure 1). The difference in means of H-FABP levels between patients with IGT or IFG and control subjects was significant ($p = 0.010$ and $p = 0.009$, respectively; Table 2). We compared the serum H-FABP levels of pre-diabetic groups; Although the IGT group had a higher serum H-FABP level



than the IFG group, the difference was not significant ($p = 0.732$).

The mean insulin resistance test (HOMA-IR) values of the IFG group, IGT group, and control group statistically differed from each other, the values were 3.4 ± 1.4, 4.1 ± 1.7, and 2.1 ± 1.0, respectively ($p < 0.001$). However, HOMA-IR values were not correlated with H-FABP levels.

CIMT was significantly higher in the pre-diabetic groups than in the control group (IFG: 0.6 ± 0.1, IGT: 0.6 ± 0.1, control: 0.5 ± 0.1; $p < 0.001$). However, there was no significant difference between the CIMT values of patients in the two pre-diabetic states. H-FABP was positively correlated with CIMT (Figure 2). In the 86 participants included in the study, a strong relationship was found between serum H-FABP and CIMT ($p < 0.001$, $\rho = 0.626$). IFG and IGT groups were examined separately; There was a significant relationship between H-FABP and CIMT (IFG group: $p < 0.001$, $\rho = 0.765$; IGT group: $p < 0.001$, $\rho = 0.613$).

No significant correlation was identified between H-FABP levels and age, gender, BMI, or other biochemical parameters.

Discussion

The present study confirms that serum levels of H-FABP are increased in patients with pre-diabetes, and, for the first time to our knowledge, demonstrates that elevated circulating serum levels of H-FABP may

Table 2 Serum heart-type fatty acid binding protein (H-FABP) levels in patients with impaired fasting glucose (IFG), patients with impaired glucose tolerance (IGT), and control subjects


Study Groups	H-FABP	
	Mean ± SD	p
IFG	32.5 ± 34.2	0.011
IGT	45.4 ± 45.8	
Control	16.8 ± 14.9	
Difference of Means ± SEM		p
IFG-IGT	-12.9 ± 10.7	0.732
IFG-control	15.8 ± 6.9	0.009
IGT-control	28.7 ± 9.0	0.010

provide important prognostic information in patients with IFG and IGT. These two pre-diabetic states were initially recognized as conditions associated with increased risk of progression to type 2 diabetes mellitus. A number of studies have demonstrated that pre-diabetes is a state of subclinical inflammation, procoagulation, and endothelial dysfunction [4-6]. The two pre-diabetic states differ from one another in many aspects, including the associated cardiovascular risk. Whereas there is ample evidence pointing out a strong relationship between IGT and cardiovascular morbidity and mortality, the relationship between IFG and cardiovascular disease

is still unclear and controversial [8,9]. An increased understanding of the cardiovascular risk associated with the two categories of pre-diabetes would be of great benefit for the development of screening programs and preventive strategies for subjects with IFG and IGT.

H-FABP is a cytoplasmic protein with a molecular weight of 15 kDa, which mediates the passage of fatty acids from the plasma membrane to sites of lipid synthesis. It has been reported that H-FABP is a potent inducer of cardiac myocyte hypertrophy, stimulating an increase in cell surface area, protein synthesis, and c-jun expression [16]. Furthermore, H-FABP has been reported to be a new specific serum biomarker for acute myocardial infarction [17,18]. Viswanathan et al. [19] have demonstrated that the prognostic value of elevated H-FABP is additive to that of troponin in low- and intermediate-risk patients with suspected ACS. H-FABP could therefore be of value as a marker of myocardial ischemia, even in the absence of frank necrosis. Orak et al. [20] found that for patients admitted to emergency service (ES) with chest pain, H-FABP was more sensitive and specific than troponin I and creatinine kinase myocardial band (CK-MB) in the early diagnosis of acute coronary syndrome. Kyung Su Kim et al [21] confirm that; the initial H-FABP measured by quantitative POCT has a better diagnostic value than initial myoglobin or initial CK-MB as an adjunct to the initial cardiac troponins for the early diagnosis of MI. Łukasz Figiel et al [22] also showed superior sensitivity of h-FABP compared to glycogen phosphorylase BB (GP-BB) and cardiac troponin T (cTnT) in patients with ACS. H-FABP has high diagnostic accuracy in early non-ST-segment elevation ACS.

Previous studies have shown that H-FABP is not only a marker of acute myocardial infarction, but of other conditions as well. Boscheri et al. [23] have reported that H-FABP significantly predicts mortality in patients with intermediate risk for pulmonary embolism. H-FABP could therefore also represent a novel prognostic parameter enabling the optimization of management strategy in the very difficult population of pulmonary embolism patients who are at intermediate risk. Akbal et al. [24] reported that patients with metabolic syndrome (MetS) have increased serum levels of H-FABP, indicating its promise as a marker for detection of cardiac injury during the early asymptomatic period in patients with MetS. Glatz JF et al. reported that experimental diabetes induces a marked increase of the FABP content of rat heart and suggests that this protein is involved in the enhanced fatty acid utilization by the diabetic heart [25]. In our study, serum H-FABP levels were significantly elevated in pre-diabetic patients compared with control subjects (IFG: 32.5 ± 34.2 ng/dL, IGT: 45.4 ± 45.8 ng/dL, control: 16.8 ± 14.9 ng/dL; p = 0.011). The difference in



means of H-FABP levels between patients with IGT or IFG and control subjects was significant ($p = 0.010$ and $p = 0.009$, respectively). Our findings also suggest that an elevated circulating level of H-FABP is not only a highly sensitive and specific marker of myocardial damage, but is also an important prognostic determinant in patients with pre-diabetes. Also, an elevated circulating level of H-FABP can reflect early identification of subclinical atherosclerosis in patients with pre-diabetes.

CIMT is an intermediate phenotype for early atherosclerosis. As it can be measured relatively simply and noninvasively, it is well suited for use in large-scale population studies. Ultrasonic measurements correlate well with histology [26], and an increased CIMT is associated with vascular risk factors and the presence of more advanced atherosclerosis [27-30], which includes coronary artery disease [31-33]. CIMT is being increasingly used for cardiac risk stratification and as an endpoint in intervention studies. An important precondition for the application of CIMT is that it can predict future risk of clinical vascular events. A number of longitudinal studies have examined the relationship between CIMT and future events, most frequently the incidence of cardiac events (specifically, myocardial infarction (MI), angina pectoris, and coronary intervention) and cerebrovascular events (stroke or transient ischemic attack) [26-33]. More recently, a clinical study in type-2 diabetics by Djaberi et al. [34] reported a significant relationship between CIMT and abnormal cardiac perfusion. Ito and coworkers [35], Escobedo and colleagues [36], and Poppe and associates [37] confirm that vascular imaging can be effectively used to detect subclinical disease in type 2 diabetics and potentially predict cardiovascular risk. Einarson TR and coworkers [38] who published a meta-analysis of data from 15,592 patients that were described in 11 papers, found significant relationship between postprandial glucose levels and CIMT, which have both been associated with adverse cardiovascular outcomes. In our study, CIMT was significantly higher in the pre-diabetic groups than in the control group (IFG: 0.6 ± 0.1 , IGT: 0.6 ± 0.1 , control: 0.5 ± 0.1 ; $p < 0.001$). However CIMT was similar in both pre-diabetic states. In contrast to previous studies, the risk appeared to be the same in the two categories of pre-diabetes. Finally, we also found a positive correlation between H-FABP levels and CIMT ($p < 0.001$, $\rho = 0.626$).

In conclusion, to the best of our knowledge, the present study is the first case-control study in which significant alteration in serum H-FABP levels was detected in patients with pre-diabetes. H-FABP levels were increased in patients with IFG and IGT, and serum H-FABP levels were positively correlated with CIMT. There was no difference between patient and control groups in other known cardiovascular risk factors, including age, sex, cholesterol panels, HT, and smoking. However, serum

H-FABP levels in patients were high and there was a positive correlation with IMT. H-FABP may therefore represent a marker for early atherosclerosis in pre-diabetic patients.

Further studies are required to investigate the relationship between H-FABP levels and long-term development of cardiac injury and atherosclerosis in patients with pre-diabetes.

Acknowledgements

We would like to thank Dr. Mustafa Sahin for providing advice in our search of the medical literature.

Author details

¹Department of Endocrinology and Metabolism, Dışkapı Yıldırım Beyazıt Teaching and Research hospital, Ankara, Turkey. ²Department of Biochemistry, Dışkapı Yıldırım Beyazıt Teaching and Research hospital, Ankara, Turkey.

Authors' contributions

First authorship is shared between BK and MÖ as both had equal contribution to study concept and design, search of the literature and the drafting and revision of the manuscript. Other authors participated in enrolling patients in the study and discussion. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 18 February 2011 Accepted: 2 May 2011

Published: 2 May 2011

References

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997, **20**:1183-97.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2000, **23**:S4-19.
3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabetic Med* 1998, **15**:539-53.
4. Zhang L, Qiao Q, Tuomilehto J, Hammar N, Alberti KG, Eliasson M, Heine RJ, Stehouwer CD, Ruotolo G, DECODE Study Group: Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: the DECODE Study. *Diabetes Res Clin Pract* 2008, **82**:364-77.
5. Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med* 2002, **19**:708-23.
6. Faeh D, William J, Yerly P, Paccaud F, Bovet P: Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. *Cardiovasc Diabetol* 2007, **6**:32.
7. Janssen PG, Gorter KJ, Stolk RP, Rutten GE: Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study. *Prim Care Diabetes* 2007, **1**:69-74.
8. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose—a review of diagnosis, clinical implications and management. *Diab Vasc Dis Res* 2005, **2**:9-15.
9. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. *Diabetes Care* 2000, **23**:1830-4.

10. Fournier NC, Richard MA: **Role of fatty acid-binding protein in cardiac fatty acid oxidation.** *Mol Cell Biochem* 1990, **98**:149-59.
11. Pelsers MM, Hermens WT, Glatz JF: **Fatty acid-binding proteins as plasma markers of tissue injury.** *Clin Chim Acta* 2005, **352**:15-35.
12. Nagahara D, Nakata T, Hashimoto A, Takahashi T, Kyuma M, Hase M, Tsuchihashi K, Shimamoto K: **Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room.** *Circ J* 2006, **70**:419-25.
13. Mitsuhashi N, Onuma T, Kubo S, Takayanagi N, Honda M, Kawamori R: **Coronary artery disease and carotid artery intima-media thickness in Japanese type 2 diabetic patients.** *Diabetes Care* 2002, **25**:1308-12.
14. Brohall G, Odén A, Fagerberg B: **Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review.** *Diabet Med* 2006, **23**:609-16.
15. World Health Organization: **Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF Consultation.** Geneva. World Health Org; 2006.
16. Burton PB, Hogben CE, Joannou CL, Clark AG, Hsuan JJ, Totty NF, Sorensen C, Evans RW, Tynan MJ: **Heart fatty acid binding protein is a novel regulator of cardiac myocyte hypertrophy.** *Biochem Biophys Res Commun* 1994, **205**:1822-8.
17. Glatz JF, Kleine AH, van Nieuwenhoven FA, Hermens WT, van Dieijen-Visser MP, van der Vusse GJ: **Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans.** *Br Heart J* 1994, **71**:135-40.
18. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K: **Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction.** *Clin Biochem* 1991, **24**:195-201.
19. Viswanathan K, Kilcullen N, Morrell C, Thistlethwaite SJ, Sivanathan MU, Hassan TB, Barth JH, Hall AS: **Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative.** *J Am Coll Cardiol* 2010, **55**:2590-8.
20. Orak M, Ustündağ M, Güloğlu C, Ozhasenekler A, Alyan O, Kale E: **The role of the heart-type fatty acid binding protein in the early diagnosis of acute coronary syndrome and its comparison with troponin I and creatine kinase-MB isoform.** *Am J Emerg Med* 2010, **28**:891-6.
21. Kim KS, Lee HJ, Kim K, Jo YH, Kim TY, Lee JH, Rhee JE, Suh GJ, Kim MR, Lee CC, Singer AJ: **Heart-type fatty acid binding protein as an adjunct to cardiac troponin-I for the diagnosis of myocardial infarction.** *J Korean Med Sci* 2011, **26**(1):47-52.
22. Figiel Ł, Wraga M, Bednarkiewicz Z, Lipiec P, Smigielski J, Krzemińska-Pakuła M, Kasprzak JD: **Direct comparison of the diagnostic value of point-of-care tests detecting heart-type fatty acid binding protein or glycogen phosphorylase isoenzyme BB in patients with acute coronary syndromes with persistent ST-segment elevation.** *Kardiol Pol* 2011, **69**(1):1-6.
23. Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedemann B, Stolte D, Elmer G, Barthel P, Strasser RH: **Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk.** *Am Heart J* 2010, **160**:294-300.
24. Akbal E, Özbek M, Güneş F, Akyürek Ö, Üreten K, Delibaşı T: **Serum heart type fatty acid binding protein levels in metabolic syndrome.** *Endocrine* 2009, **36**:433-7.
25. Glatz JF, van Breda E, Keizer HA, de Jong YF, Lakey JR, Rajotte RV, Thompson A, van der Vusse GJ, Lopaschuk GD: **Rat heart fatty acid-binding protein content is increased in experimental diabetes.** *Biochem Biophys Res Commun* 1994, **199**(2):639-46.
26. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R: **Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging.** *Circulation* 1986, **74**:1399-406.
27. Salonen JT, Salonen R: **Ultrasound B-mode imaging in observational studies of atherosclerotic progression.** *Circulation* 1993, **87**:1156-65.
28. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: **Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study.** *Circulation* 1997, **96**:1432-437.
29. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX: **Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993.** *Am J Epidemiol* 1997, **146**:483-94.
30. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr: **Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults.** Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 1999, **340**:14-22.
31. Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JC: **Carotid intima-media thickness at different sites: relation to incident myocardial infarction; The Rotterdam Study.** *Eur Heart J* 2002, **23**:934-40.
32. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B: **Incident coronary events and case fatality in relation to common carotid intima-media thickness.** *J Intern Med* 2005, **257**:430-37.
33. Lorenz MW, von Kogler S, Steinmetz H, Markus HS, Sitzer M: **Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS).** *Stroke* 2006, **37**:87-92.
34. Djaberi R, Schuijff JD, de Koning EJ, Rabelink TJ, Smit JW, Kroft LJM, Pereira AM, Scholte AJ, Spaans M, Romijn JA, de Roos A, van der Wall EE, Wouter Jukema J, Bax JJ: **Usefulness of carotid intima-media thickness in patients with diabetes mellitus as a predictor of coronary artery disease.** *Am J Cardiol* 2009, **104**:1041-1046.
35. Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M: **The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study.** *Cardiovasc Diabetol* 2010, **9**:18.
36. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinuesa R, Torres M, Hernandez R, Wilson E: **Prevalence of metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross-sectional study.** *Cardiovasc Diabetol* 2009, **8**:52.
37. Poppe KK, Whalley GA, Somaratne JB, Keelan S, Bagg W, Triggs CM, Doughty RN: **The role of echocardiographic left ventricular mass and carotid intima-media thickness in the cardiovascular risk assessment of asymptomatic patients with type 2 diabetes mellitus.** *Intern Med J* 2010.
38. Einarson TR, Hunchuck J, Hemels M: **Relationship between blood glucose and carotid intima media thickness: A meta-analysis.** *Cardiovasc Diabetol* 2010, **9**:37.

doi:10.1186/1475-2840-10-37

Cite this article as: Karbek et al.: Heart-Type Fatty Acid Binding Protein (H-FABP): Relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with impaired glucose metabolism. *Cardiovascular Diabetology* 2011 **10**:37.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

